Objective: To analyze and evaluate the rationality of clinical medication of anti-tumor drugs, and to provide reference for rational use of antitumor drugs. Methods: 114 prescriptions containing anti-tumor drugs were taken from tumor patients admitted to gynecology department from July to December 2018. The clinical use of anti-tumor drugs prescribed by doctors was analyzed, and the rationality, reasons and countermeasures of the clinical use of anti-tumor drugs (such as solvent variety, solvent quantity, drug delivery order, intravenous infusion rate, etc.) were evaluated according to the "comment standard". Results: Among the 114 medical orders for the medication of anti-tumor drugs, 103 medical orders were reasonable (the reasonable rate was 90.35%), and 11 medical orders were unreasonable (9.65%). The reasons for unreasonable drug use were: 2 cases (18.18%) were used beyond the authority of doctors, 2 cases (18.18%) were used at inappropriate infusion rate, 4 cases (36.36%) were given at inappropriate infusion sequence, 1 case (9.09%) was not fully hydrated, and 2 cases (18.18%) were improperly kept and used for infusion. Conclusion: The clinical medication of anti-tumor drugs is generally reasonable, but it still needs to be further improved. When necessary, therapeutic drug monitoring (TDM) should be carried out. At the same time, the attention should be paid to adverse drug reactions and efficacy, and as well as minimizing the occurrence of adverse drug reactions, so as to ensure the safety, effectiveness, rationality and individualization of drug use.